Méthodes Statistiques pour la médecine personnalisée

Membres de l’équipe

Delphine Héquet, MD-PhD

Delphine Héquet Equipe Latouche PH Retour à la liste

PhD in Oncology (ED582) and MD in Surgery, my research is essentially centered on breast cancer, and mostly based on real-life data including SNDS (Système National des Données de Santé), observational studies (OPTISOINS 01 - ClinicalTrial Identifier NCT02813317), cohort studies (CANTO - ClinicalTrial Identifier NCT01993498), register studies (OPTIBOT - ClinicalTrial Identifier NCT03690440), retrospective studies (ClinicalTrials.gov Identifier: NCT03275311) and e-cohort studies (Seintinelles).

The impact of surgery in terms of survival in 2 situations is poorly known: in case of de novo metastatic breast cancer and in case of re-operation after positive margins in conservative breast cancer surgery. To explore these issues, and identify (bio-)markers, we have recourse to several real-life data but also a phase 2 prospective study (PALATINE; sponsor : Unicancer; PI : D. Héquet). This study aims to evaluate the impact of breast locoregional treatment in case of de novo metastatic patients; biological samples (breast, metastasis and cDNA) at several steps of the management of the patients will help to identify predictive biomarkers of improved global survival in case of surgery.

In another hand, and in relation to de novo metastatic disease, extension assessment of breast cancer is currently not standardized exceeding the indications of INCa recommendations. Studying the real use of extension assessment in several populations (early breast cancer, de novo metastatic breast cancer) will help to identify the relevant indications and the medico-economic impact of the not justified examinations.

The other axes studies include : adhesion to treatment, (CANTO), impact of active accompaniment on return to work after cancer, impact of HPV vaccination on the occurrence of dysplasia, impact of ovarian conservative surgery in case of borderline tumor on survival and fertility.